Peptides As Versatile Regulators in Cancer Immunotherapy: Recent Advances, Challenges, and Future Prospects

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Jan 25

PMID 39861694

Authors

Yu Lei

Jiacheng Liu

Yaowei Bai

Chuansheng Zheng

Dongyuan Wang

Affiliations

Soon will be listed here.

Abstract

The emergence of effective immunotherapies has revolutionized therapies for many types of cancer. However, current immunotherapy has limited efficacy in certain patient populations and displays therapeutic resistance after a period of treatment. To address these challenges, a growing number of immunotherapy drugs have been investigated in clinical and preclinical applications. The diverse functionality of peptides has made them attractive as a therapeutic modality, and the global market for peptide-based therapeutics is witnessing significant growth. Peptides can act as immunotherapeutic agents for the treatment of many malignant cancers. However, a systematic understanding of the interactions between different peptides and the host's immune system remains unclear. This review describes in detail the roles of peptides in regulating the function of the immune system for cancer immunotherapy. Initially, we systematically elaborate on the relevant mechanisms of cancer immunotherapy. Subsequently, we categorize peptide-based nanomaterials into the following three categories: peptide-based vaccines, anti-cancer peptides, and peptide-based delivery systems. We carefully analyzed the roles of these peptides in overcoming the current barriers in immunotherapy, including multiple strategies to enhance the immunogenicity of peptide vaccines, the synergistic effect of anti-cancer peptides in combination with other immune agents, and peptide assemblies functioning as immune stimulators or vehicles to deliver immune agents. Furthermore, we introduce the current status of peptide-based immunotherapy in clinical applications and discuss the weaknesses and future prospects of peptide-based materials for cancer immunotherapy. Overall, this review aims to enhance comprehension of the potential applications of peptide-based materials in cancer immunotherapy and lay the groundwork for future research and clinical applications.

References

Lozano T, Gorraiz M, Lasarte-Cia A, Ruiz M, Rabal O, Oyarzabal J . Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. Oncotarget. 2017; 8(42):71709-71724. PMC: 5641083. DOI: 10.18632/oncotarget.17845. View

Yan X, Zhu P, Li J . Self-assembly and application of diphenylalanine-based nanostructures. Chem Soc Rev. 2010; 39(6):1877-90. DOI: 10.1039/b915765b. View

Cen L, Zhang Z, Sun Y, Wu N, Shao J, Qian Z . Efficacy of MAGE-A4 long peptide as a universal immunoprevention cancer vaccine. Cancer Cell Int. 2024; 24(1):232. PMC: 11223347. DOI: 10.1186/s12935-024-03421-2. View

Song W, Kuang J, Li C, Zhang M, Zheng D, Zeng X . Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor Eradication. ACS Nano. 2018; 12(2):1978-1989. DOI: 10.1021/acsnano.7b09112. View

Russick J, Torset C, Hemery E, Cremer I . NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends. Semin Immunol. 2020; 48:101407. DOI: 10.1016/j.smim.2020.101407. View

Sui X, Niu X, Zhou X, Gao Y . Peptide drugs: a new direction in cancer immunotherapy. Cancer Biol Med. 2023; 21(3). PMC: 10976324. DOI: 10.20892/j.issn.2095-3941.2023.0297. View

Wang T, Wang D, Yu H, Feng B, Zhou F, Zhang H . A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. Nat Commun. 2018; 9(1):1532. PMC: 5906566. DOI: 10.1038/s41467-018-03915-4. View

Orafaie A, Bahrami A, Matin M . Use of anticancer peptides as an alternative approach for targeted therapy in breast cancer: a review. Nanomedicine (Lond). 2021; 16(5):415-433. DOI: 10.2217/nnm-2020-0352. View

Zhu Y, Tang K, Lv J . Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci. 2021; 42(10):857-869. DOI: 10.1016/j.tips.2021.07.001. View

10.

Vincent C, Remeseiro S . The immune response behind peptide vaccination in diffuse midline glioma. Mol Oncol. 2024; 18(8):1849-1852. PMC: 11306526. DOI: 10.1002/1878-0261.13686. View

11.

Bojarska J, Wolf W . Short Peptides as Powerful Arsenal for Smart Fighting Cancer. Cancers (Basel). 2024; 16(19). PMC: 11476321. DOI: 10.3390/cancers16193254. View

12.

Kumthekar P, Tang S, Brenner A, Kesari S, Piccioni D, Anders C . ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020; 26(12):2789-2799. DOI: 10.1158/1078-0432.CCR-19-3258. View

13.

Koido S, Taguchi J, Shimabuku M, Kan S, Bito T, Misawa T . Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer. J Immunother Cancer. 2024; 12(10). PMC: 11474828. DOI: 10.1136/jitc-2024-009765. View

14.

Fleming S, Ulijn R . Design of nanostructures based on aromatic peptide amphiphiles. Chem Soc Rev. 2014; 43(23):8150-77. DOI: 10.1039/c4cs00247d. View

15.

Diao Y, Han W, Zhao H, Zhu S, Liu X, Feng X . Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain. J Pept Sci. 2012; 18(7):476-86. DOI: 10.1002/psc.2420. View

16.

Hatziioannou A, Alissafi T, Verginis P . Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force. J Leukoc Biol. 2017; 102(2):407-421. DOI: 10.1189/jlb.5VMR1116-493R. View

17.

Zhang W, Li D, Xu X, Chen Y, Shi X, Pan Y . A Bispecific Peptide-Polymer Conjugate Bridging Target-Effector Cells to Enhance Immunotherapy. Adv Healthc Mater. 2023; 12(18):e2202977. DOI: 10.1002/adhm.202202977. View

18.

Li M, Wang Z, Liu X, Song N, Song Y, Shi X . Adaptable peptide-based therapeutics modulating tumor microenvironment for combinatorial radio-immunotherapy. J Control Release. 2021; 340:35-47. DOI: 10.1016/j.jconrel.2021.10.026. View

19.

Gottschalk S, Yu F, Ji M, Kakarla S, Song X . A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. PLoS One. 2013; 8(12):e82658. PMC: 3861387. DOI: 10.1371/journal.pone.0082658. View

20.

Futaki S . Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev. 2005; 57(4):547-58. DOI: 10.1016/j.addr.2004.10.009. View